Portfolio news Archives - Page 13 of 13

T3 Pharmaceuticals wins W.A. de Vigier Award

T3 Pharmaceuticals is among the winners of this year’s W.A. de Vigier Award. The spin-off from the University of Basel is developing a targeted cancer…

clement28.05.2019

Portfolio news

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

Leading venture capital firm Sofinnova Partners led the Series A financing, together with New Enterprise Associates, which co-led the round Basel, Switzerland, 28 March 2019–Polyneuron…

clement28.03.2019

Human immune cells can eliminate cancer cells. Anaveon has developed a special antibody to boost the body’s own defense mechanism. The picture shows an electron-microscopic view of one of the immune system’s CD8 killer cells. (Image: NIAID/flickr)

Portfolio news

BaseLaunch backed Anaveon received funding

Onur Boyman, an immunologist working at the University Hospital Zurich and UZH, has joined forces with Andreas Katopodis to establish Anaveon, a BaseLaunch participant. Aiming to translate…

clement20.06.2018

Portfolio news

BaseLaunch accelerated Polyneuron raises new financing

Polyneuron Pharmaceuticals, a BaseLaunch participant, has successfully raised over 3 million Swiss francs in a financing round. The Basel-based pharmaceutical company is developing an active…

clement14.05.2018

Portfolio news

Biotech VCs are backing more rounds and making bigger bets

Biotech is a lot like venture capital. Vast amounts of research, testing and marketing go into a wide range of therapies. But in the end,…

clement10.03.2018

Portfolio news

T3 Pharmaceuticals wins W.A. de Vigier Award

Polyneuron raises CHF 22.5 Million in Series A to advance novel Therapies for Autoimmune Diseases

BaseLaunch backed Anaveon received funding

BaseLaunch accelerated Polyneuron raises new financing

Biotech VCs are backing more rounds and making bigger bets

Useful links

Contact us

Sign up for our newsletter and event invitations

Follow us